Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference

COLUMBUS, Ga., Feb. 26 Aflac Incorporated(NYSE: AFL) announced today that it will make a presentation at the RaymondJames 29th Annual Institutional Investors Conference. President and ChiefFinancial Officer Kriss Cloninger III will represent Aflac Incorporated, andhe is scheduled to make a presentation on March 4 at 10:25 a.m. EST. Duringthe Aflac Incorporated presentation, Mr. Cloninger will discuss the company'soutlook for 2008 and its strategy for growth in the U.S. and Japaneseinsurance markets.

Mr. Cloninger's presentation will be webcast live at the following webaddress:

http://www.wsw.com/webcast/rj33/afl/

For more than 50 years, Aflac products have given policyholders theopportunity to direct cash where it is needed most when a life-interruptingmedical event causes financial challenges. Aflac is the number one provider ofguaranteed-renewable insurance in the United States and the number oneinsurance company in terms of individual insurance policies in force in Japan.

Our insurance products provide protection to more than 40 million peopleworldwide. Aflac has been included in Fortune magazine's listing of America'sMost Admired Companies for seven consecutive years and in Fortune magazine'slist of the 100 Best Companies to Work For in America for ten consecutiveyears. Aflac has also been recognized three times by both Fortune magazine'slisting of the Top 50 Employers for Minorities and Working Mother magazine'slisting of the 100 Best Companies for Working Mothers. Aflac Incorporated is aFortune 500 company listed on the New York Stock Exchange under the symbolAFL. To find out more about Aflac, visit aflac.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO )

Analyst and investor contact - Kenneth S. Janke Jr.,800.235.2667 - option 3, FAX: 706.324.6330, or [email protected]

Media contact - Laura Kane, 706.596.3493, FAX: 706.320.2288, [email protected]

SOURCE Aflac Incorporated

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...